ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 101 for:    celiac disease | Recruiting, Not yet recruiting, Available Studies

Gut Permeability Assessment in Celiac and Gluten Sensitive Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02690532
Recruitment Status : Recruiting
First Posted : February 24, 2016
Last Update Posted : August 17, 2017
Sponsor:
Information provided by (Responsible Party):
Imad Absah, Mayo Clinic

Brief Summary:
This study will assess the effect of gluten on gut barrier function. Investigators at the Mayo Clinic have developed a new gut permeability test using rhamnose (sugar & water solution), and are hoping to prove its effectiveness in a clinical setting.

Condition or disease
Celiac Disease

Detailed Description:
The aim of this study is to assess effect of gluten on the gut barrier function in patients at high risk for celiac disease and non-celiac gluten sensitivity (NCGS) patients. This study will assess the gut permeability in three groups of patients 1) children who are at high risk for developing celiac disease (CD) (siblings of patients with celiac disease), 2) Children who are self-diagnosed with NCGS and 3) control group of patients matched for age and gender. Patients will undergo celiac serologic and genetic testing, after which the rhamnose test will be performed to assess the presence of increased gut permeability.

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: The Role of Gut Permeability in Developing Celiac Disease and Non-Celiac Gluten Sensitivity
Study Start Date : March 2016
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine


Group/Cohort
High risk group
Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease).
Non-celiac group
Children who are self-diagnosed with non-celiac gluten sensitivity.
Control Group
Healthy control group (matched for age and gender).



Primary Outcome Measures :
  1. Gut Permeability [ Time Frame: Baseline ]
    Assess the effect of gluten on gut permeability in children at high risk of developing celiac disease or gluten sensitivity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study population will consist of three groups of children, aged 2-17 years. The first group will be children with siblings that have celiac disease, the second group will be children with non-celiac gluten sensitivity and the third group will be healthy children.
Criteria

High Risk group:

  • Sibling with a confirmed diagnosis of celiac disease
  • No history Celiac disease or any other bowel disease

Non-Celiac Gluten Sensitivity group:

  • Self-diagnosis of gluten sensitivity
  • No history of celiac disease or other bowel disease

Healthy group:

  • Absence of celiac disease or any other bowel disease
  • No sensitivity to gluten

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02690532


Contacts
Contact: James Allen 507-255-9899 Allen.James1@mayo.edu

Locations
United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Principal Investigator: Imad Absah, MD         
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Imad Absah, MD Mayo Clinic

Responsible Party: Imad Absah, M.D., Assistant Professor of Pediatrics, Mayo Clinic
ClinicalTrials.gov Identifier: NCT02690532     History of Changes
Other Study ID Numbers: 15-006018
First Posted: February 24, 2016    Key Record Dates
Last Update Posted: August 17, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Imad Absah, Mayo Clinic:
Celiac
Gluten
Sensitivity
Permeability
Non-celiac gluten intolerance
Gastrointestinal Diseases
Digestive System Diseases

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases